Related Experiment Video
Updated: Aug 28, 2025

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
Identification of the Regulatory Targets of miR-3687 and miR-4417 in Prostate Cancer Cells Using a Proteomics
Simone Venz1, Heike Junker1, Erik Ultsch1
1Department of Medical Biochemistry and Molecular Biology, University Medicine Greifswald, 17475 Greifswald, Germany.
Abstract:
MicroRNAs (miRNA) are ubiquitous non-coding RNAs that have a prominent role in cellular regulation. The expression of many miRNAs is often found deregulated in prostate cancer (PCa) and castration-resistant prostate cancer (CRPC). Although their expression can be associated with PCa and CRPC, their functions and regulatory activity in cancer development are poorly understood. In this study, we used different proteomics tools to analyze the activity of hsa-miR-3687-3p (miR-3687) and hsa-miR-4417-3p (miR-4417), two miRNAs upregulated in CRPC. PCa and CRPC cell lines were transfected with miR-3687 or miR-4417 to overexpress the miRNAs. Cell lysates were analyzed using 2D gel electrophoresis and proteins were subsequently identified using mass spectrometry (Maldi-MS/MS). A whole cell lysate, without 2D-gel separation, was analyzed by ESI-MS/MS. The expression of deregulated proteins found across both methods was further investigated using Western blotting. Gene ontology and cellular process network analysis determined that miR-3687 and miR-4417 are involved in diverse regulatory mechanisms that support the CRPC phenotype, including metabolism and inflammation. Moreover, both miRNAs are associated with extracellular vesicles, which point toward a secretory mechanism. The tumor protein D52 isoform 1 (TD52-IF1), which regulates neuroendocrine trans-differentiation, was found to be substantially deregulated in androgen-insensitive cells by both miR-3687 and miR-4417. These findings show that these miRNAs potentially support the CRPC by truncating the TD52-IF1 expression after the onset of androgen resistance.
Insights
Two microRNAs, miR-3687 and miR-4417, are upregulated in castration-resistant prostate cancer (CRPC). These microRNAs (miRNAs) regulate key processes like metabolism and inflammation, potentially promoting CRPC progression by affecting tumor protein D52 isoform 1.
Area of Science:
- Molecular Biology
- Cancer Research
- Proteomics
Background:
- MicroRNAs (miRNAs) are crucial regulators of cellular processes, with deregulated expression observed in prostate cancer (PCa) and castration-resistant prostate cancer (CRPC).
- The specific roles and regulatory functions of many dysregulated miRNAs in cancer development remain largely unelucidated.
Purpose of the Study:
- To investigate the functional roles and regulatory activities of hsa-miR-3687-3p (miR-3687) and hsa-miR-4417-3p (miR-4417) in CRPC.
- To identify protein targets and cellular pathways influenced by these upregulated miRNAs in CRPC.
Main Methods:
- Overexpression of miR-3687 and miR-4417 in PCa and CRPC cell lines.
- Proteomic analysis using 2D gel electrophoresis, Maldi-MS/MS, and ESI-MS/MS.
- Validation of protein expression changes via Western blotting.
- Bioinformatic analysis including Gene Ontology and pathway analysis.
Main Results:
- miR-3687 and miR-4417 are involved in diverse regulatory mechanisms supporting the CRPC phenotype, including metabolism and inflammation.
- Both miRNAs are associated with extracellular vesicles, suggesting a secretory role.
- Tumor protein D52 isoform 1 (TD52-IF1), a regulator of neuroendocrine trans-differentiation, was significantly deregulated by both miRNAs in androgen-insensitive cells.
Conclusions:
- miR-3687 and miR-4417 play a significant role in supporting the CRPC phenotype.
- These miRNAs may promote CRPC progression by modulating TD52-IF1 expression, particularly after the development of androgen resistance.
Related Concept Videos
MicroRNAs
Proteomics
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...

